Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma.

BACKGROUND Hepatocellular carcinoma (HCC) often recurs after curative hepatectomy; and early recurrence after hepatectomy (ERAH) is associated with poor prognosis. This study aimed to clarify risk factors and disease patterns for ERAH. METHODS We retrospectively analyzed clinicopathological factors of 232 patients who underwent initial curative hepatectomies for HCC between April 2000 and March 2013, and examined associated risk factors and early recurrence patterns by liver function status (as indicated by indocyanine green retention rate at 15 min [ICGR15]). RESULTS Patients who experienced recurrence within 6 months after hepatectomy (i.e., ERAH) had significantly shorter survival than those with longer disease-free intervals (P < 0.001). In multivariate analysis, microvascular invasion (mVI; P = 0.034) and ICGR15 ≥ 16% (P = 0.010) were independent risk factors for ERAH. In the ICGR1<16% subgroup, positive L3-AFP (P = 0.04), tumor size ≥ 5 cm (P = 0.011), surgical margin = 0 (P = 0.0103), mVI (P = 0.034), and extrahepatic recurrence were significant predictors of ERAH; in the ICGR15 ≥ 16%, subgroup, multiple tumors (P = 0.046) were identified as a risk factor for ERAH; however, this group did not experience much extrahepatic recurrence. CONCLUSIONS ERAH was associated with mVI and ICGR15 ≥ 16%. Recurrence patterns and risk factors vary by liver function status, which should be considered in forming management strategies for early recurrence of HCC after curative hepatectomy.

[1]  S. Fan,et al.  Prediction of Posthepatectomy Recurrence of Hepatocellular Carcinoma by Circulating Cancer Stem Cells: A Prospective Study , 2011, Annals of surgery.

[2]  K. Komeda,et al.  A novel method using the VIO soft-coagulation system for liver resection. , 2011, Surgery.

[3]  S. Du,et al.  A prospective clinical study on early recurrence of hepatocellular carcinoma after hepatectomy , 2009, Journal of surgical oncology.

[4]  T. Kanematsu,et al.  Predictor for Histological Microvascular Invasion of Hepatocellular Carcinoma: A Lesson from 229 Consecutive Cases of Curative Liver Resection , 2010, World Journal of Surgery.

[5]  Hongxiang Liu,et al.  CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma , 2011, BMC Cancer.

[6]  J. Lee,et al.  Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. , 2006, American journal of surgery.

[7]  S. Fan,et al.  Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma , 2000, Cancer.

[8]  Y. Qiu,et al.  Adjuvant Therapy With Capecitabine Postpones Recurrence of Hepatocellular Carcinoma After Curative Resection: A Randomized Controlled Trial , 2010, Annals of Surgical Oncology.

[9]  K. Shirabe,et al.  Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. , 1996, Gastroenterology.

[10]  Masatoshi Tanaka,et al.  Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[11]  L. Capussotti,et al.  Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  Chiun Hsu,et al.  Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. , 2010, Journal of hepatology.

[13]  M. Monden,et al.  Interferon-β Is More Potent Than Interferon-α in Inhibition of Human Hepatocellular Carcinoma Cell Growth When Used Alone and in Combination With Anticancer Drugs , 2003, Annals of Surgical Oncology.

[14]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[15]  K. Chayama,et al.  Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—A prospective randomized study of hepatitis C virus–related liver cancer , 2000, Hepatology.

[16]  H. Moriwaki,et al.  Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. , 1996, Digestion.

[17]  S. Kawasaki,et al.  Surgery for small liver cancers. , 1993, Seminars in surgical oncology.

[18]  A. Tamori,et al.  Effects of Long-Term Postoperative Interferon- Therapy on Intrahepatic Recurrence after Resection of Hepatitis C VirusRelated Hepatocellular Carcinoma , 2001, Annals of Internal Medicine.

[19]  K. Endo,et al.  Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. , 2000, Journal of hepatology.

[20]  S. Kawasaki,et al.  Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. , 2003, Journal of hepatology.

[21]  A. Burroughs,et al.  A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability , 2012, Annals of Surgical Oncology.

[22]  A J Davis,et al.  Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. , 2000, The Lancet. Oncology.

[23]  Y. Shibayama,et al.  Clinicopathological Risk Factors for Recurrence within One Year after Initial Hepatectomy for Hepatocellular Carcinoma , 2011, The American surgeon.

[24]  C. Sakakura,et al.  Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy. , 2015, World journal of gastroenterology.

[25]  W. Lau,et al.  Partial Hepatectomy With Wide Versus Narrow Resection Margin for Solitary Hepatocellular Carcinoma: A Prospective Randomized Trial , 2007, Annals of surgery.

[26]  I. Ng,et al.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells. , 2007, Gastroenterology.

[27]  X. Guan,et al.  CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway , 2008, Oncogene.

[28]  S. Fan,et al.  Significance of CD90+ cancer stem cells in human liver cancer. , 2008, Cancer cell.

[29]  S. Gallinger,et al.  Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. , 2006, Journal of the American College of Surgeons.

[30]  K. Boudjema,et al.  Adjuvant intra‐arterial injection of iodine‐131–labeled lipiodol after resection of hepatocellular carcinoma , 2003, Hepatology.

[31]  Yasuo Ohashi,et al.  Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial , 2000, The Lancet.